Tuesday, April 13, 1:00 to 2:00 PM PST
Even in a pandemic, technology and markets are global and many companies are interested in exploring opportunities in different geographies. Once a deal is established in principle, how does one go about a cross-border transaction that implicates the laws and nuances of multiple countries? This talk will cover cross-border M&A, international equity raising, and cross-border intellectual property licensing.
https://www.youtube.com/watch?v=77bk2By7kw4
Thursday, May 27, 1:00 to 2:00 PM PST
Ever-increasing costs have kept the topic of healthcare coverage, reimbursement, and pricing in the spotlight. While innovators must be sensitive to the short-term goals of their investors, those “quick wins” in the development or regulatory phases may stymie the efficient attainment of long-term goals for favorable coverage and payment by public and commercial health insurers. Value has become a buzzword, but what does it mean? And what does it mean to different audiences? While some feel the assessment of value is opaque and challenging, health insurers (buyers) believe that the message is clear enough but largely ignored because it doesn’t match what developers (sellers) want to hear.
https://www.youtube.com/watch?v=Gpy_FTgnPAg
Thursday, March 11, 1:00 to 3:00 PM PST
“Build a better mousetrap and the world will beat a path to your door,” the old saying goes. Unfortunately, that’s not true in healthcare. Incumbent incentives, conservative cultures, regulations, reimbursement, and inertia all create obstacles to the best ideas having impact. Healthcare entrepreneurs who succeed know how the system works, and how to work within the evolving system.
In depth topics covered will include the challenges different types of players are facing (and how to help them address those challenges), who buys what (and why), reimbursement dynamics, what drives adoption, and changing consumer healthcare preferences – with plenty of time for Q&A (so bring your questions!).
Sam Glick, partner at Oliver Wyman and leader of the Oliver Wyman Health Innovation Center, will draw on his work with payers, providers, employers, and life sciences companies to share an integrated view of the dynamics of the US healthcare system, and what entrepreneurs need to do to succeed.
https://www.youtube.com/watch?v=biParI3mZsY
Check out session 1 video recording and slide deck here.
Thursday, March 18, 1:00 to 3:00 PM PST
“Build a better mousetrap, and the world will beat a path to your door,” the old saying goes. Unfortunately, that’s not true in healthcare. Incumbent incentives, conservative cultures, regulations, reimbursement, and inertia all create obstacles to the best ideas having an impact. Healthcare entrepreneurs who succeed know how the system works, and how to work within the evolving system.
In-depth topics covered will include the challenges different types of players are facing (and how to help them address those challenges), who buys what (and why), reimbursement dynamics, what drives adoption, and changing consumer healthcare preferences – with plenty of time for Q&A (so bring your questions!).
Sam Glick, partner at Oliver Wyman and leader of the Oliver Wyman Health Innovation Center, will draw on his work with payers, providers, employers, and life sciences companies to share an integrated view of the dynamics of the US healthcare system, and what entrepreneurs need to do to succeed.
Thursday, February 25, 1:00 to 3:30 PM PST
Join Dennis Boyle, IDEO co-founder/partner, and Delphine Huang, IDEO Medical Director, for a 2.5-hour interactive workshop on brainstorming as a team in a digital/remote setting. Focused specifically on health early-stage startups and Rosenman founders, we will be covering how to use design-thinking techniques and tools to creatively brainstorm, synthesize insights, and move towards iterative prototyping.
IDEO is a global design company. They create a positive impact through design.
Our Workshops are hosted by leading experts who have generously offered their services pro bono to our entrepreneurs.If you are selected, we will require a $100 credit card deposit. The deposit will be refunded the day after you attend. No-shows will not receive a refund. Please be punctual; arrivals late by more than 15 minutes will be considered no-shows. If you find that you are unable to attend, you may request a refund up to 5 days in advance. (This will give us time to offer the slot to the first person on the waitlist.) We regret that we cannot honor requests made at a later time.
https://www.youtube.com/watch?v=d-q2kthXNvU
Tuesday, February 9, 1:00 to 2:00 PM PST
Most emerging companies with rapid growth plans will seek venture financing. Whether you sell SAFE, convertible notes, or preferred stock, venture investors expect that your financing will feature standard rights and use accepted documentation, but that isn’t the end of the story. Decisions about valuation, founders’ rights, and control over decision making can have long-lasting impacts on the company, and the interests of the investors will quickly deviate from those of the original stockholders. It is important to understand the financing process, where there is room to negotiate, and which investor rights are non-negotiable. This talk will walk through the process of a typical venture investment, starting at the term sheet stage and moving through the definitive documents. We will focus on real-life examples and the consequences of certain decisions in the lead-up to closing.
Zoom Webinar
Tuesday, January 26, 1:00 to 2:00 PM PST
Livongo Health is one of the biggest all-time successes in digital health. The company “offers a whole person platform that empowers people with chronic conditions to live better and healthier lives.” In 2019, Livongo made its debut on the Nasdaq at $355 million, and saw a premium of nearly 45% over its IPO price. Now, a year later, telehealth giant Teladoc is merging with Livongo in a deal worth as much as $18.5 billion, reflecting the growing importance of virtual healthcare platforms. Join us to hear founder Glen Tullman’s story of how he built Livongo.
https://www.youtube.com/watch?v=sdSKxs5OxWc
Zoom Webinar
Wednesday, January 20, 1:00 to 2:00 PM PST
Employers are a critical stakeholder in the US healthcare system: 49% of Americans receive health coverage through their employer, and employers spend $1.2T on healthcare today. Given this, the employer market is a natural starting point for emerging healthcare companies. But what do employers want, and how is this changing? How should emerging healthcare companies position themselves to address employer concerns? How should healthcare companies selling directly to employers think about other market stakeholders – brokers, health plans, PBMs, providers? During this talk, we will address all three of these questions, and share lessons learned from healthcare technology companies that have built successful businesses in the employer-sponsored market.
https://www.youtube.com/watch?v=NgDToFiRQSU&feature=youtu.be
Zoom Webinar
Tuesday, December 8, 1:00 to 2:00 PM PST
Agreements are the lifeblood of any emerging company. License agreements typically allow founders to bring their technology out of the academic setting and into their companies. Master service agreements are a very common avenue by which emerging companies work with vendors to accomplish research objectives. Collaboration agreements typically define relationships between a company and an industry partner or larger strategic. Understanding these agreements and avoiding pitfalls are critical. This talk with explain the different aspects of such agreements and how they are viewed by venture investors and other strategic partners.
Zoom Webinar
Wednesday, November 11, 1:00 to 2:00 PM PST
2020 has been an unbelievably difficult year for everyone and has thrown special obstacles in the way of startup founders. Doing labwork, pitching investors, conducting trials: it can seem like nothing is easy or even possible. Yet you can make progress. Who could confirm this better than Harith Rajagopalan, CEO of Fractyl? Fractyl, whose technology treats patients with type 2 diabetes, received an Investigational Device Exemption from the FDA this June; and in August closed a $55 million round to fund global clinical trials. How did Harith do it?